Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SENP3 | Q9H4L4 | 2/20 | 0.36 |
| ▸ | SENP2 | Q9HC62 | 2/20 | 0.36 |
| ▸ | SENP1 | Q9P0U3 | 2/20 | 0.36 |
| ▸ | SUMO2 | P61956 | 1/20 | 0.36 |
| ▸ | SUMO1 | P63165 | 1/20 | 0.36 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.36 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.34 |
| ▸ | CASP6 | P55212 | 2/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | RAD1 | O60671 | 1/20 | 0.34 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.34 |
| ▸ | TIMP3 | P35625 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | SNCA | P37840 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Disufenton SCHEMBL13916412 | 1.00 | SENP3 (0.36) | SENP3SENP2SENP1SUMO2SUMO1 | |
| Disufenton SCHEMBL29385168 | 1.00 | SENP3 (0.36) | SENP3SENP2SENP1SUMO2SUMO1 | |
| Disufenton SCHEMBL1922127 | 0.98 | SENP3 (0.35) | SENP3SENP2SENP1SUMO2SUMO1 | |
| SCHEMBL13488468 | 0.91 | SMN1; SMN2 (0.38) | ENPP2ALDH1A1RAD1P2RY6LMNA | |
| SCHEMBL5553705 | 0.85 | SENP3 (0.33) | SENP3SENP2SENP1SUMO2SUMO1 | |
| SCHEMBL5549780 | 0.85 | SENP3 (0.33) | SENP3SENP2SENP1SUMO2SUMO1 | |
| SCHEMBL20848694 | 0.84 | TDP1 (0.36) | SENP3SENP2SENP1SUMO2SUMO1 | |
| SCHEMBL10293546 | 0.84 | SENP3 (0.37) | SENP3SENP2SENP1SUMO2SUMO1 | |
| SCHEMBL6449477 | 0.83 | KMT2A (0.38) | ALDH1A1HSD17B10CYP2C9CYP2C19TDP1 | |
| SCHEMBL15216504 | 0.81 | KMT2A (0.38) | ALDH1A1HSD17B10CYP2C9CYP2C19TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11020354-B2 | Formulations of n-acetylcysteine and uses thereof | OTOLOGIC PHARMACEUTICALS, INC. (US) | 2021-06-01 | — | — | US | claimed |
| WO-2018136605-A1 | FORMULATIONS OF N-ACETYLCYSTEINE AND USES THEREOF | Otologic Pharmaceutics, Inc. (US) | 2018-07-26 | — | — | WO | claimed |
| US-20180200192-A1 | FORMULATIONS OF N-ACETYLCYSTEINE AND USES THEREOF | Otologic Pharmaceutics, Inc. (US) | 2018-07-19 | — | — | US | claimed |
| JP-2011524851-A | — | — | 2011-09-08 | — | — | JP | claimed |
| EP-2242360-A2 | DOXORUBICIN ADJUVANTS TO REDUCE TOXICITY AND METHODS FOR USING THE SAME | Tosk, Inc. (US) | 2010-10-27 | — | — | EP | claimed |
| WO-2009102808-A2 | DOXORUBICIN ADJUVANTS TO REDUCE TOXICITY AND METHODS FOR USING THE SAME | TOSK, INCORPORATED (US) | 2009-08-20 | — | — | WO | claimed |
| US-11660280-B2 | Treatment of drug resistant gliomas | OKLAHOMA MEDICAL RESEARCH FOUNDATION (US) | 2023-05-30 | — | — | US | disclosed |
| EP-2670403-B1 | METHODS FOR TREATING BRAIN INJURY | HOUGH EAR INST (US) | 2021-08-18 | — | — | EP | disclosed |
| US-11084852-B2 | Ubiquitin interacting motif peptides as therapeutics | OKLAHOMA MEDICAL RESEARCH FOUNDATION (US) | 2021-08-10 | — | — | US | disclosed |
| US-11020354-B2 | Formulations of n-acetylcysteine and uses thereof | OTOLOGIC PHARMACEUTICALS, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| US-20200215015-A1 | TREATMENT OF DRUG RESISTANT GLIOMAS | OKLAHOMA MEDICAL RESEARCH FOUNDATION (US) | 2020-07-09 | — | — | US | disclosed |
| CN-110392568-A | Preparation of N-acetylcystein and application thereof | 耳科制药公司 | 2019-10-29 | — | — | CN | disclosed |
| US-10398659-B2 | Adjuvant chemotherapy for anaplastic gliomas | OKLAHOMA MEDICAL RESEARCH FOUNDATION (US) | 2019-09-03 | — | — | US | disclosed |
| WO-2001051459-A1 | METHOD FOR THE PURIFICATION OF ARYL SULFONIC ACIDS AND SALTS | CENTAUR PHAMACEUTICALS, INC. (US) | 2001-07-19 | — | — | WO | disclosed |
| US-6258852-B1 | NITRONE COMPOUNDS FOR TREATMENT OF INFLAMMATORY DISEASE | CENTAUR PHARMACEUTICALS, INC. | 2001-07-10 | — | — | US | disclosed |
| EP-1077694-A1 | ARYL NITRONE THERAPEUTICS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | CENTAUR PHARMACEUTICALS, INC. (US) | 2001-02-28 | — | — | EP | disclosed |
| US-6083989-A | ADMINISTERING TO THE PATIENT SUFFERING FROM INFLAMMATORY BOWL MOVEMENT AN N-SUBSTITUTED ARYL NITRON COMPOUND OR SALT | CENTAUR PHARMACEUTICALS, INC. (US) | 2000-07-04 | — | — | US | disclosed |
| EP-0736004-B1 | (2,4-DISULFOPHENYL) N-TERTIARY BUTYL NITRONE, ITS SALTS, AND THEIR USE AS PHARMACEUTICAL RADICAL TRAPPING AGENTS | OKLAHOMA MED RES FOUND (US) | 2000-05-10 | — | — | EP | disclosed |
| WO-1999059576-A1 | ARYL NITRONE THERAPEUTICS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | CENTAUR PHARMACEUTICALS, INC. (US) | 1999-11-25 | — | — | WO | disclosed |
| US-5780510-A | TREATING CONCUSSION OR SUBARACHNOID HEMORRHAGE | OKLAHOMA MEDICAL RESEARCH FOUNDATION (US) | 1998-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180200192-A1 | FORMULATIONS OF N-ACETYLCYSTEINE AND USES THEREOF | MGMT, GCLC, AANAT | SENP3 986/4885SENP2 987/4885SENP1 1201/4885 |
| US-11020354-B2 | Formulations of n-acetylcysteine and uses thereof | MGMT, GCLC, AANAT | SENP3 986/4885SENP2 987/4885SENP1 1201/4885 |
| US-11084852-B2 | Ubiquitin interacting motif peptides as therapeutics | UBXN1, UBQLN1, UFM1 | SENP3 108/4885SENP2 202/4885SENP1 115/4885 |
| US-20200215015-A1 | TREATMENT OF DRUG RESISTANT GLIOMAS | MGMT, NES, DCX | SENP3 786/4885SENP2 733/4885SENP1 1366/4885 |
| US-11660280-B2 | Treatment of drug resistant gliomas | MGMT, NES, DCX | SENP3 786/4885SENP2 733/4885SENP1 1366/4885 |
| US-10398659-B2 | Adjuvant chemotherapy for anaplastic gliomas | TRIB2, NES, DCX | SENP3 1714/4885SENP2 2206/4885SENP1 2583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.